Core Viewpoint - Elite Pharmaceuticals is conducting its Third Quarter of Fiscal Year 2026 Conference Call, indicating a focus on discussing financial performance and future expectations [1]. Group 1: Company Overview - The conference call is hosted by Mr. Nasrat Hakim, the President and CEO of Elite Pharmaceuticals, who will lead the discussion on the company's performance and outlook [4]. Group 2: Forward-Looking Statements - Elite Pharmaceuticals has issued a reminder that the remarks made during the call may contain forward-looking statements that involve risks and uncertainties, which are subject to change [2]. - The company emphasizes that actual results may differ materially from those anticipated in forward-looking statements, and it disclaims any obligation to update or revise these statements except as required by law [3].

Thomas Appio: Thank you, Garen, and welcome to everyone joining our earnings call today. Our year concluded with an impressive eleventh consecutive quarter of growth in both revenue and adjusted EBITDA, reflecting our organization's consistent performance. This success is powered by our global team’s unwavering commercial focus and operational excellence, as full year results exceeded our guidance on all key metrics. The fourth quarter gave us an opportunity to reflect on the progress we have made over the ...

Bausch Health (NYSE:BHC) Q4 2025 Earnings call February 18, 2026 05:00 PM ET Company ParticipantsGaren Sarafian - VP and Head of Investor RelationsGlen Santangelo - Managing DirectorJJ Charhon - EVP and CFOJonathan Sadeh - CMO and Head of Research and DevelopmentLes Sulewski - VP of Spec Pharma and Biotech Equity ResearchThomas Appio - CEOUmer Raffat - Equity Research of Biotech, Pharma-major, and Specialty PharmaConference Call ParticipantsMichael Freeman - Equity Research AnalystNone - AnalystNone - Analy ...

Bausch Health (NYSE:BHC) Q4 2025 Earnings call February 18, 2026 05:00 PM ET Company ParticipantsGaren Sarafian - VP and Head of Investor RelationsGlen Santangelo - Managing DirectorJJ Charhon - EVP and CFOJonathan Sadeh - CMO and Head of Research and DevelopmentLes Sulewski - VP of Spec Pharma and Biotech Equity ResearchThomas Appio - CEOUmer Raffat - Equity Research of Biotech, Pharma-major, and Specialty PharmaConference Call ParticipantsMichael Freeman - Equity Research AnalystNone - AnalystNone - Analy ...

Financial Data and Key Metrics Changes - Bausch Health reported a revenue increase of 9% in Q4 2025 compared to Q4 2024, reaching $2,796 million, with adjusted EBITDA rising by 13% to $1,052 million [10][11] - For the full year 2025, revenue grew by 7% and adjusted EBITDA by 10%, indicating strong operational performance [18][19] - Adjusted gross margin was 71.6%, down 80 basis points year-over-year, while adjusted operating expenses increased by $75 million to $1,033 million [10][11] Business Line Data and Key Metrics Changes - Salix revenue in Q4 was $693 million, a 9% increase year-over-year, driven by strong demand and promotional efforts [12] - Solta Medical segment revenues decreased by 1% to $137 million, impacted by distributor transition in China, but would have shown mid-single-digit growth without this effect [15][16] - The diversified segment saw a 12% revenue increase to $255 million, primarily due to improved net pricing [16] Market Data and Key Metrics Changes - International segment revenues were $306 million, up 10% on a reported basis, with EMEA and LatAm showing double-digit growth, while Canada contracted by 6% [13][14] - The Latin American market returned to growth with a 22% revenue increase, while Canada faced challenges due to increased generic competition [14][15] Company Strategy and Development Direction - The company aims to enhance operational assets through innovation and optimize brand growth globally, with a focus on business development opportunities [21][22] - The acquisition of Shibo's aesthetics distribution platform in China is expected to strengthen the company's market presence and enhance direct engagement with providers [7][26] - Strategic priorities for 2026 include maximizing shareholder value and optimizing the capital structure following significant refinancing [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong cash generation and improved capital structure, allowing for proactive business development [5][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance range of $5.25 billion to $5.4 billion [20][21] - Management acknowledged the disappointment regarding the RED-C trial results but remains focused on advancing other development opportunities [9] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow for the year and reduced net debt by approximately $320 million in Q4 [7][12] - The debt maturity profile was improved by approximately $1.7 billion through a debt exchange, providing additional flexibility for future opportunities [7][19] Q&A Session Summary Question: Post RED-C readout, what is the updated decision framework for separation and debt repayments? - Management stated there is no change in focus, continuing to prioritize debt repayment and reinvestment in the business [33] Question: Can you provide more details about business development plans? - Management is screening various assets for potential acquisitions, leveraging their strong commercial team [36][37] Question: What is the impact of the Shibo integration on revenue and EBITDA growth? - The integration is progressing well, with a minor EBITDA impact of $10-$15 million due to accounting adjustments [45][47] Question: What are the expectations for Xifaxan generics? - Management confirmed that a generic is expected by January 1, 2028, and is focused on maximizing current value [84] Question: What is the EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would likely be around $2.7 billion, reflecting a dip compared to 2025 [86]

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/ultragenyx-pharmaceutical-inc-loss-submission-form-2/?id=183592&fro ...

Company Overview - ORIC is participating in Citi's 2026 Virtual Oncology Leadership Summit, with CEO Jacob Chacko and CFO Dominic Piscitelli present for discussions [1]. - The session aims to provide insights into ORIC's operations, particularly focusing on their prostate cancer program [2]. Key Discussion Points - The discussion will begin with a high-level overview of ORIC, followed by specific questions regarding their prostate cancer initiatives [2].

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form-2/?id=183596&from=3 CLA ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section o. ...

Group 1: Ceasefire Monitoring in Ukraine - Ukrainian President Volodymyr Zelenskyy confirmed a constructive agreement in Geneva regarding a potential ceasefire, with the U.S. leading the monitoring mechanism alongside European allies [2] - Despite progress on monitoring, talks remain challenging with unresolved issues regarding occupied territories and the Zaporizhzhia Nuclear Power Plant [3] - Market participants are closely monitoring these developments, as a formal truce could significantly impact the SPDR S&P 500 ETF Trust (SPY) and defense contractors like Lockheed Martin (LMT) [3][4] Group 2: U.S. Biotech Industry Challenges - FDA Commissioner Marty Makary warned that the U.S. is losing its competitive edge in early-stage drug development to China, citing bottlenecks in hospital contracting, ethical reviews, and the IND application process [5] - U.S. firms spent over $4.2 billion last year to license compounds from Chinese labs, with companies like AstraZeneca (AZN) announcing multi-billion dollar deals for Chinese-developed drugs [6] - The FDA is proposing reforms to streamline manufacturing approvals and reduce reliance on animal studies, but these efforts may face challenges from staffing cuts and shifting federal priorities, impacting the iShares Biotechnology ETF (IBB) and the broader healthcare sector [7]